Ipilimumab and nivolumab: the 'new kid on the block' in advanced angiosarcoma

Immunotherapy. 2023 Oct;15(14):1089-1091. doi: 10.2217/imt-2023-0110. Epub 2023 Aug 10.
No abstract available

Keywords: angiosarcoma; cancer; checkpoint; immunotherapy; sarcoma; soft tissue.

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents, Immunological* / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols
  • Hemangiosarcoma* / drug therapy
  • Humans
  • Ipilimumab / therapeutic use
  • Nivolumab / therapeutic use

Substances

  • Nivolumab
  • Ipilimumab
  • Antineoplastic Agents, Immunological